ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 105 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $10,846,884 | -19.7% | 540,722 | +12.9% | 0.00% | -33.3% |
Q2 2023 | $13,507,033 | +84.0% | 478,803 | +12.2% | 0.00% | +200.0% |
Q1 2023 | $7,342,180 | -13.2% | 426,871 | +1.6% | 0.00% | -50.0% |
Q4 2022 | $8,459,686 | -6.3% | 420,044 | +0.7% | 0.00% | 0.0% |
Q3 2022 | $9,033,000 | -14.0% | 417,042 | +11.5% | 0.00% | 0.0% |
Q2 2022 | $10,506,000 | -32.9% | 373,900 | +10.2% | 0.00% | -33.3% |
Q1 2022 | $15,652,000 | -46.8% | 339,231 | -3.0% | 0.00% | -40.0% |
Q4 2021 | $29,401,000 | +26.7% | 349,765 | +0.4% | 0.01% | +25.0% |
Q3 2021 | $23,213,000 | +42.0% | 348,332 | +13.3% | 0.00% | +33.3% |
Q2 2021 | $16,351,000 | +33.0% | 307,330 | +8.5% | 0.00% | +50.0% |
Q1 2021 | $12,293,000 | -16.2% | 283,323 | +0.3% | 0.00% | -33.3% |
Q4 2020 | $14,670,000 | +211.9% | 282,442 | +96.3% | 0.00% | +200.0% |
Q3 2020 | $4,704,000 | -26.1% | 143,892 | +8.6% | 0.00% | -50.0% |
Q2 2020 | $6,364,000 | – | 132,536 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Decheng Capital Management III (Cayman), LLC | 1,824,583 | $39,520,000 | 14.33% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,301,771 | $49,857,000 | 4.79% |
Matrix Capital Management Company, LP | 9,199,973 | $199,271,000 | 3.81% |
Integral Health Asset Management, LLC | 550,000 | $11,913,000 | 2.31% |
Avidity Partners Management LP | 4,223,100 | $91,472,000 | 1.86% |
Affinity Asset Advisors, LLC | 170,000 | $3,682,000 | 1.03% |
Eventide Asset Management | 1,861,000 | $40,309,000 | 0.79% |
Sofinnova Investments, Inc. | 583,357 | $12,636,000 | 0.74% |
Nicholas Investment Partners, LP | 158,704 | $3,438,000 | 0.32% |
SECTORAL ASSET MANAGEMENT INC | 60,000 | $1,300,000 | 0.26% |